Radius Health (RDUS) PT Raised to $52 at Cantor Fitzgerald

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and boosted her price target on Radius Health (NASDAQ: RDUS) to $52.00 (from $26.00) following positive phase 3 trials of Abaloparatide-SC.

"With the first hurdle (18-month data) achieved, we believe that abaloparatide-SC is significantly de-risked, prompting us to raise our PT to $52 from $26," Goldstein said. "This is based on a lowering of the discount rate to 20% vs. 30% on future abaloparatide-SC sales forecast, yielding $46 per share. RAD-1901 contributes an additional $6, in our view, suggesting a valuation of $52 per share. With the second hurdle - the six-month extension study (24-month fracture data) likely in 1H:15, we believe abaloparatide-SC will be further de-risked, suggesting additional upside. The company expects an NDA to be filed in 2H:15 with the FDA."

For an analyst ratings summary and ratings history on Radius Health click here. For more ratings news on Radius Health click here.

Shares of Radius Health closed at $37.45 yesterday.

You May Also Be Interested In

• Amazon.com (AMZN) PT Raised to $215 at UBS
• Weatherford International plc (WFRD) PT Raised to $184 at Piper Sandler
• City Holding (CHCO) PT Raised to $110 at Keefe, Bruyette & Woods